Giebel Sebastian
Giebel Sebastian
Treatment algorithms differ for adult patients with Philadelphia-negative (Ph-) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). For Ph- ALL intensive induction-consolidation chemotherapy using "pediatric-inspired" protoc...
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations [0.03%]
门诊CAR-T细胞治疗的标准治疗现状及考虑因素
Katie Gatwood,Zahra Mahmoudjafari,Brittney Baer et al.
Katie Gatwood et al.
Chimeric antigen receptor T-cell therapy (CAR-T) has altered the treatment landscape of several hematologic malignancies. Until recently, most CAR-T infusions have been administered in the inpatient setting, due to their toxicity profile. H...
Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis [0.03%]
接受血液透析的多发性骨髓瘤患者使用Elranatamab治疗
Zoé Van de Wyngaert,Irene Romera-Martinez,Céline Chedeville et al.
Zoé Van de Wyngaert et al.
We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific a...
Andrew M Brunner,Uwe Platzbecker,Amy E DeZern et al.
Andrew M Brunner et al.
Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbiditi...
Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States [0.03%]
美国住院患者中种族差异导致浆细胞白血病预后不良
Cindy Wu,Deepa Dongarwar,Samer Al Hadidi
Cindy Wu
Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma (MM) with a poor prognosis. Prior studies have shown that racial disparities affect MM patients in various ways, which may affect patients' outcomes. In this study...
Standing on the Shoulders of the Giants: Dr. Alain Fischer [0.03%]
站在巨人的肩膀上——献给阿尔明·夏尔教授及菲利普·亨利·斯塔宾斯博士的文章之阿兰·菲舍尔教授
Mohamad Mohty,Alain Fischer
Mohamad Mohty
Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand? [0.03%]
鲁索利替尼在难治/复发霍奇金淋巴瘤治疗中的应用：我们目前处于什么阶段？
Ahmed H Al Sharie,Balqis M Abu Mousa,Ahmad O Alomari
Ahmed H Al Sharie
Marwa Alhamss,Riad El Fakih
Marwa Alhamss
The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma [0.03%]
多发性骨髓瘤当前正在入组的维持治疗临床试验的景观分析
Syed Maaz Tariq,Al-Ola Abdallah,Aaron Goodman et al.
Syed Maaz Tariq et al.
Maintenance therapies in multiple myeloma improve survival after induction treatment. This study characterizes the strategies for maintenance therapy being employed in currently enrolling clinical trials for patients with multiple myeloma a...